- ROUNDTABLE: Pharmacy’s future in sync with technology
- Actavis seeks approval for generic opioid-dependence drug
- Harvard Heart Letter: Many consumers who supplement with aspirin don't need to
- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- Lumene unveils product innovation, new packaging for 2014
WOODCLIFF LAKE, N.J. — Par Pharmaceutical Cos. has entered into agreements with Watson Pharmaceuticals and Actavis to purchase five generic products currently marketed in the United States by Watson or Actavis, eight abbreviated new drug applications currently awaiting regulatory approval, and a generic product in late-stage development.
The five currently marketed products covered by the acquisition include morphine sulfate extended-release capsules, the generic version of Kadian; fentanyl transdermal system CII, the generic equivalent of Duragesic; nifedipine extended-release tablets, the generic version of Adalat CC; diltiazem hydrochloride extended-release capsules, the generic equivalent of Cardizem CD; and metoclopramide hydrochloride tablets, the generic version of Reglan.
The purchase of the products is contingent on the closing of Watson's acquisition of Actavis. Par expects to begin shipping these products to the trade immediately following the purchase.